New Data from CytoReason published in Gut outlines the role of a new technological platform approach that has revealed a new blood-based biomarker that is 94% accurate in pretreatment identification of anti-TNFα non-responders in inflammatory bowel disease (IBD), accounting for approximately 30% of patients, confirming validity of the approach.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,